WO2014119984A3 - Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor - Google Patents

Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor Download PDF

Info

Publication number
WO2014119984A3
WO2014119984A3 PCT/MX2014/000027 MX2014000027W WO2014119984A3 WO 2014119984 A3 WO2014119984 A3 WO 2014119984A3 MX 2014000027 W MX2014000027 W MX 2014000027W WO 2014119984 A3 WO2014119984 A3 WO 2014119984A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
pharmaceutically acceptable
biphasic
immediate
controlling
Prior art date
Application number
PCT/MX2014/000027
Other languages
English (en)
French (fr)
Other versions
WO2014119984A2 (es
Inventor
Miguel Ángel GARCIA PÉREZ
Gabriel MARCELÍN JIMÉNEZ
Concepción Albina VÁZQUEZ FLORES
Ricardo David ÁVILA CEDILLO
Alionka Citlalli P. ANGELES MORENO
Octavio CARO RODRÍGUEZ
Original Assignee
Garcia Pérez Miguel Ángel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garcia Pérez Miguel Ángel filed Critical Garcia Pérez Miguel Ángel
Publication of WO2014119984A2 publication Critical patent/WO2014119984A2/es
Publication of WO2014119984A3 publication Critical patent/WO2014119984A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas para su uso en el control, prevención o tratamiento de eventos convulsivos y/o dolor que comprenden un sistema de entrega bifásica que comprende: 1) una tableta que comprende al menos un análogo del ácido gamma-aminobutirico y/o sus sales farmacéuticamente aceptables, profármacos, metabolitos, polimorfos, amorfos, hidratos, derivados; y/o al menos un agente diluyente; y/o al menos un agente aglutinante; y/o al menos un agente desintegrante y/o al menos un agente lubricante; y/o al menos un excipiente farmacéuticamente aceptable; y 2) una tableta que comprende al menos una vitamina del grupo B y/o sus sales farmacéuticamente aceptables, profármacos, metabolitos, polimorfos, amorfos, hidratos, derivados; y/o al menos un agente aglutinante; y/o al menos un agente diluyente; y/o al menos un agente lubricante; y/o al menos un agente de recubrimiento; y/o al menos un excipiente farmacéuticamente aceptable.
PCT/MX2014/000027 2013-01-31 2014-01-28 Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor WO2014119984A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2013001278A MX2013001278A (es) 2013-01-31 2013-01-31 Composicion farmaceutica con un sistema bifasico de liberacion inmediata para el control de eventos convulsivos y del dolor.
MXMX/A/2013/001278 2013-01-31

Publications (2)

Publication Number Publication Date
WO2014119984A2 WO2014119984A2 (es) 2014-08-07
WO2014119984A3 true WO2014119984A3 (es) 2014-11-27

Family

ID=51263088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000027 WO2014119984A2 (es) 2013-01-31 2014-01-28 Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor

Country Status (2)

Country Link
MX (1) MX2013001278A (es)
WO (1) WO2014119984A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019010949A2 (pt) 2017-01-11 2019-10-01 Ferring Bv composição farmacêutica de desintegração rápida
WO2024068242A1 (en) * 2022-09-29 2024-04-04 Triviumvet Designated Activity Company Veterinary compositions for use in the treatment of neuropathic pain
WO2024165618A1 (en) * 2023-02-07 2024-08-15 Kinast Lasse An immediate-release tablet of pregabalin with an increased percentage api content

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985843A (en) * 1995-04-03 1999-11-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing sucralfate
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
WO2012016683A2 (en) * 2010-08-03 2012-02-09 Ratiopharm Gmbh Oral dosage form of pregabalin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985843A (en) * 1995-04-03 1999-11-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing sucralfate
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
WO2012016683A2 (en) * 2010-08-03 2012-02-09 Ratiopharm Gmbh Oral dosage form of pregabalin

Also Published As

Publication number Publication date
MX2013001278A (es) 2014-07-30
WO2014119984A2 (es) 2014-08-07

Similar Documents

Publication Publication Date Title
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EP3791869A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES COMPRISING THE COX2 ACETYLATING AGENT AS ACTIVE INGREDIENT
EP4000609A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
MX2020012989A (es) Agente terapeutico para la fibrosis.
EP4081201A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MANY INFLAMMATORY DISORDERS
WO2014119984A3 (es) Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor
EP3766508A4 (en) RAW RESIN COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
EP3617211A4 (en) PHARMACEUTICAL COMPOSITION INTENDED TO PREVENT OR TREAT DISEASES RELATED TO AGING, CONTAINING A DERIVATIVE OF DECURSIN AS ACTIVE SUBSTANCE
WO2011113000A8 (en) Novel ester containing compositions and methods
EP3936124A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES
EP3895719A4 (en) PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SAKEI WIKIM30 AS AN ACTIVE SUBSTANCE TO PREVENT OR TREAT CANCER
EP3946296A4 (en) EXTENDED RELEASE PHARMACEUTICAL FORMULATION
EP3785715A4 (en) Pharmaceutical composition comprising ibrutinib as effective ingredient for preventing or treating degenerative brain disease
EP3659584A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISORDERS, CONTAINING HDL-APOM-S1P AS ACTIVE INGREDIENT
EP3360581A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH INHIBITOR OF PLRG1 (PLEIOTROPER REGULATOR 1) AS AN ACTIVE SUBSTANCE
HK1163526A1 (en) A medicament for treating schizophrenia comprising cilostazol
EP4082561A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, CONTAINING GLP-2 OR A CONJUGATE THEREOF
IL307803A (en) Pharmaceutical hydronidone formulations for diseases
EP3922310A4 (en) PHARMACEUTICAL COMPOSITION INTENDED TO PREVENT INTRA-STENT RESTENOSIS

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14746227

Country of ref document: EP

Kind code of ref document: A2